Figure 2

Evaluation of spleen immune cell content in omeprazole and saline treated C57BL/6J mice. Quantitation of spleen immune cells from flow cytometry analysis in saline and omeprazole treated C57BL/6J mice was performed on Day 18 post-encephalitogen (A, B), which was at an early clinical stage (clinical scores: saline 2.36 +/- 0.84, n = 7 vs. omeprazole 1.21. +/- 0.15, n = 7; p = 0.15) and Day 46 post-encephalitogen (C, D), which was during an advanced disease stage (clinical scores: saline 4.14 +/- 0.7, n = 7 vs. omeprazole 4.14 +/- 0.14, n = 7; p = 1.0). No differences in the percent of naïve (CD44^loCD62L^hi), CM (CD44^hiCD62L^hi) or EM (CD44^hiCD62L^lo) CD4+ or CD8+ cells (from parent CD4+ or CD8+ populations) were observed following omeprazole treatment vs. saline during both stages of EAE. Black bars, saline treatment; white bars, omeprazole treatment.